Fig. 1
From: The molecular tumor burden index as a response evaluation criterion in breast cancer
Mutational characteristics. a Mutational spectrum of the top 20 genes at pretreatment from 117 patients. b Percentage of patients with and without actionable targets for treatment. c Genes indicated by the OncoKB knowledge base for which targeted drugs are Food and Drug Administration (FDA)-approved
